Liver cancer patients with high amounts of Acetyl-CoA synthetase 2 (ACSS2), an enzyme that helps break down acetate, tend to have a better outlook than those with low amounts, according to a study by Kyung Hee Jung and team. This evidence concerns the gene ACSS1 and liver cancer.